News

Aligning Science Across Parkinson’s (ASAP) and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) are together investing $261 million in new grant funding to better understand what drives Parkinson’s disease and to accelerate the development of more personalized therapies. The monies will expand the Collaborative…

Routine gut biopsies may turn up evidence of protein misfolding, predicting the risk of developing neurodegenerative diseases such as Parkinson’s disease years before neurological symptoms appear, a study suggested. Researchers from the University of Aberdeen, NHS Grampian, and NHS Highland found that more than half of people who had digestive…

In Parkinson’s disease, toxic clumps of alpha-synuclein protein not only damage brain cells but also weaken the lining of blood vessels, with both processes likely working together to drive disease progression, according to a study by researchers from Binghamton University in New York and Drexel University in Philadelphia. “Parkinson’s…

Women with Parkinson’s disease are far less likely than men to undergo deep brain stimulation (DBS), in part because they are less likely to have reliable support and more likely to worry about being a burden on their loved ones. That’s according to the study, “How Women…

While on long-term treatment with Abbvie’s experimental oral drug tavapadon, most people with early Parkinson’s disease did not need to start levodopa — the mainstay therapy for the progressive condition — and most individuals already taking levodopa didn’t need to increase their dose. That’s according to new results…

A new experimental oral therapy called VQ-101 successfully reached the brain and increased the activity of a key protective protein in people with Parkinson’s disease, according to early trial results. The Phase 1 study showed that the treatment, developed by Vanqua Bio,…

BlueRock Therapeutics’ investigational cell therapy bemdaneprocel continues to show potential to control motor symptoms in people with Parkinson’s disease, with the benefits of a single dose sustained for up to three years in a small Phase 1 trial. These findings from the Phase 1 exPDite study (NCT04802733),…

People with Parkinson’s disease who switch from other levodopa/carbidopa formulations to Vyalev (foscarbidopa and foslevodopa) usually see uncontrolled movements stop within a few months of making the switch, according to a new analysis of data from two clinical trials. A team including scientists at AbbVie, the company…

People with Parkinson’s disease who switch from other formulations of levodopa to Crexont may experience improvements in daily symptom control, according to new data from an ongoing clinical trial. “Crexont substantially increased [good on] time, reduced [off time], and improved motor function in [Parkinson’s] patients across all therapy…

The U.S. Food and Drug Administration (FDA) has given a green light to the new Cala kIQ Plus system, Cala Health’s next-generation wearable neurostimulation device for helping control hand tremor during movement in people with Parkinson’s disease. The system is an update of the earlier approved Cala…